Indication
Choroidal Melanoma
7 clinical trials
6 products
Product
AU-011Clinical trial
A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal MelanomaStatus: Completed, Estimated PCD: 2021-01-26
Product
Light-activated AU-011Clinical trial
A Prospective Group-Matched Study of Visual Outcomes in Subjects Treated With Belzupacap Sarotalocan (AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)Status: Terminated, Estimated PCD: 2023-02-01
Clinical trial
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous MelanomaStatus: Active (not recruiting), Estimated PCD: 2027-01-20
Product
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1Clinical trial
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaStatus: Recruiting, Estimated PCD: 2026-03-01
Product
BelzupacapProduct
Sham TreatmentClinical trial
Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal MelanomaStatus: Completed, Estimated PCD: 2012-02-01
Product
Blood samplingClinical trial
Study of Circulating Tumoral DNA Evolution in Plasma in Choroidal MelanomaStatus: Completed, Estimated PCD: 2019-04-02